featured
Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial
JAMA Oncol 2022 Jul 14;[EPub Ahead of Print], MHG Katz, Q Shi, J Meyers, JM Herman, M Chuong, BM Wolpin, S Ahmad, R Marsh, L Schwartz, S Behr, WL Frankel, E Collisson, J Leenstra, TM Williams, G Vaccaro, A Venook, JA Meyerhardt, EM O'ReillyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.